Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stake Lowered by Strs Ohio

Strs Ohio cut its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 2.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,400 shares of the company’s stock after selling 600 shares during the quarter. Strs Ohio’s holdings in Syndax Pharmaceuticals were worth $570,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in Syndax Pharmaceuticals in the 3rd quarter worth approximately $143,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Syndax Pharmaceuticals by 6.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,192 shares of the company’s stock worth $613,000 after purchasing an additional 2,700 shares during the period. Yelin Lapidot Holdings Management Ltd. acquired a new stake in Syndax Pharmaceuticals in the third quarter worth approximately $1,663,000. China Universal Asset Management Co. Ltd. lifted its position in Syndax Pharmaceuticals by 97.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,782 shares of the company’s stock worth $26,000 after purchasing an additional 880 shares during the period. Finally, Teacher Retirement System of Texas lifted its position in Syndax Pharmaceuticals by 5.1% in the third quarter. Teacher Retirement System of Texas now owns 15,619 shares of the company’s stock worth $227,000 after purchasing an additional 757 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Scotiabank downgraded Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and cut their target price for the stock from $36.00 to $23.00 in a research report on Wednesday, January 31st. JPMorgan Chase & Co. upped their target price on Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. HC Wainwright restated a “buy” rating and issued a $41.00 target price on shares of Syndax Pharmaceuticals in a research report on Friday. Finally, StockNews.com upgraded Syndax Pharmaceuticals to a “sell” rating in a research report on Friday, January 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.42.

Syndax Pharmaceuticals Stock Up 2.4 %

SNDX opened at $21.06 on Friday. The stock has a fifty day moving average of $22.67 and a 200-day moving average of $19.61. The firm has a market capitalization of $1.79 billion, a P/E ratio of -7.11 and a beta of 1.03. Syndax Pharmaceuticals, Inc. has a 12-month low of $11.22 and a 12-month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Tuesday, February 27th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.01). During the same quarter in the prior year, the firm posted ($0.62) earnings per share. On average, analysts expect that Syndax Pharmaceuticals, Inc. will post -3.7 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).